New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure

No Thumbnail Available
File version
Author(s)
Toljan, K
Amin, M
Kunchok, A
Ontaneda, D
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2022
Size
File type(s)
Location
License
Abstract

Background: Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine. The association cannot be determined to be causal, as latent central nervous system demyelinating disease may unmask itself in the setting of an infection or a systemic inflammatory response. We report a series of 5 cases of newly diagnosed MS following recent exposure to mRNA COVID-19 vaccines. Latency from vaccination to initial presentation varied. Neurological manifestations and clinical course appeared to be typical for MS including response to high dose steroids in 4 cases and additional need for plasmapheresis in one case. Conclusion: Acute neurological deficits in the setting of recent mRNA COVID-19 vaccine administration may represent new onset multiple sclerosis.

Journal Title

Journal of Neuroimmunology

Conference Title
Book Title
Edition
Volume

362

Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Immunology

Neurosciences

COVID-19

COVID-19 vaccines

Coronavirus

Diagnosis

Multiple sclerosis

Persistent link to this record
Citation

Toljan, K; Amin, M; Kunchok, A; Ontaneda, D, New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure, Journal of Neuroimmunology, 2022, 362, pp. 577785

Collections